CA3235307A1 - T cell immunotherapy derived from highly functional autologous stem cell memory cells - Google Patents

T cell immunotherapy derived from highly functional autologous stem cell memory cells Download PDF

Info

Publication number
CA3235307A1
CA3235307A1 CA3235307A CA3235307A CA3235307A1 CA 3235307 A1 CA3235307 A1 CA 3235307A1 CA 3235307 A CA3235307 A CA 3235307A CA 3235307 A CA3235307 A CA 3235307A CA 3235307 A1 CA3235307 A1 CA 3235307A1
Authority
CA
Canada
Prior art keywords
cells
antigen
population
tscm
lag3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235307A
Other languages
English (en)
French (fr)
Inventor
Yassine Taoufik
Marie-Ghislaine Madeleine De Goer De Herve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Original Assignee
Institut Gustave Roussy
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay filed Critical Institut Gustave Roussy
Publication of CA3235307A1 publication Critical patent/CA3235307A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
CA3235307A 2021-10-26 2022-10-26 T cell immunotherapy derived from highly functional autologous stem cell memory cells Pending CA3235307A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306493 2021-10-26
EP21306493.4 2021-10-26
PCT/EP2022/080008 WO2023073062A1 (en) 2021-10-26 2022-10-26 T cell immunotherapy derived from highly functional autologous stem

Publications (1)

Publication Number Publication Date
CA3235307A1 true CA3235307A1 (en) 2023-05-04

Family

ID=78709377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235307A Pending CA3235307A1 (en) 2021-10-26 2022-10-26 T cell immunotherapy derived from highly functional autologous stem cell memory cells

Country Status (7)

Country Link
US (1) US20250017961A1 (cg-RX-API-DMAC7.html)
EP (1) EP4423247A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538258A (cg-RX-API-DMAC7.html)
CN (1) CN118251487A (cg-RX-API-DMAC7.html)
AU (1) AU2022374955A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235307A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023073062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026514981A (ja) * 2023-04-26 2026-05-13 ユニヴェルシテ パリ-サクレー 自己幹細胞メモリーt細胞由来のt細胞免疫療法
WO2025210263A1 (en) 2024-04-05 2025-10-09 Assistance Publique - Hôpitaux De Paris T cell immunotherapy of cutaneous diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
KR20180099768A (ko) * 2015-12-30 2018-09-05 노파르티스 아게 증진된 효능을 갖는 면역 이펙터 세포 요법
EP3701041A4 (en) * 2017-10-27 2021-11-17 The Trustees of The University of Pennsylvania METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASES ASSOCIATED WITH EXHAUSTED T-CELLS

Also Published As

Publication number Publication date
CN118251487A (zh) 2024-06-25
US20250017961A1 (en) 2025-01-16
AU2022374955A1 (en) 2024-05-23
EP4423247A1 (en) 2024-09-04
WO2023073062A1 (en) 2023-05-04
JP2024538258A (ja) 2024-10-18

Similar Documents

Publication Publication Date Title
US12296010B2 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
CN106074601B (zh) 用于细胞免疫治疗的方法和组合物
CN111727242A (zh) 用于活化、修饰和扩增γδT细胞治疗癌症和相关恶性肿瘤的方法
CN108697737A (zh) 在免疫疗法中使用的组合物
US20250017961A1 (en) T cell immunotherapy derived from highly functional autologous stem cell memory t cells
CN113260369B (zh) 癌抗原特异性细胞毒性t细胞
EP4702129A1 (en) T cell immunotherapy derived from autologous stem cell memory t cells
WO2025210263A1 (en) T cell immunotherapy of cutaneous diseases
WO2022066100A1 (en) Methods for improved t cell manufacturing
HK40118579A (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
HK40029406A (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
EA045258B1 (ru) СПОСОБЫ АКТИВАЦИИ, МОДИФИКАЦИИ И ЭКСПАНСИИ γδ T-КЛЕТОК ДЛЯ ЛЕЧЕНИЯ РАКА И СВЯЗАННЫХ С НИМ ЗЛОКАЧЕСТВЕННЫХ ЗАБОЛЕВАНИЙ
HK1234096B (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
HK1234096A1 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
NZ763755B2 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
NZ726346B2 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250930